Dexamethasone 12 mg versus 6 mg for patients with COVID-19 and severe hypoxaemia: a pre-planned, secondary Bayesian analysis of the COVID STEROID 2 trial

MLA

Granholm, Anders, et al. “Dexamethasone 12 Mg versus 6 Mg for Patients with COVID-19 and Severe Hypoxaemia: A Pre-Planned, Secondary Bayesian Analysis of the COVID STEROID 2 Trial.” Intensive Care Medicine, vol. 48, no. 1, Jan. 2022, p. 45. EBSCOhost, https://doi.org/10.1007/s00134-021-06573-1.

APA

Granholm, A., Munch, M. W., Myatra, S. N., Vijayaraghavan, B. K. T., Cronhjort, M., Wahlin, R. R., & Jakob, S. M. (2022). Dexamethasone 12 mg versus 6 mg for patients with COVID-19 and severe hypoxaemia: a pre-planned, secondary Bayesian analysis of the COVID STEROID 2 trial. Intensive Care Medicine, 48(1), 45. https://doi.org/10.1007/s00134-021-06573-1

Chicago

Granholm, Anders, Marie Warrer Munch, Sheila Nainan Myatra, Bharath Kumar Tirupakuzhi Vijayaraghavan, Maria Cronhjort, Rebecka Rubenson Wahlin, and Stephan M. Jakob. 2022. “Dexamethasone 12 Mg versus 6 Mg for Patients with COVID-19 and Severe Hypoxaemia: A Pre-Planned, Secondary Bayesian Analysis of the COVID STEROID 2 Trial.” Intensive Care Medicine 48 (1): 45. doi:10.1007/s00134-021-06573-1.